Aktuelle Ausgaben des Atherosclerosis-Newsletters

Dezember 2019Auf unserer Website finden Sie wieder die aktuellen Ausgaben des Atherosclerosis Newsletters, der Zusammenfassungen von thematisch zusammenhängenden Artikeln einer Ausgabe von Atherosclerosis enthält (verfasst von Simona Negrini und Arnold von Eckardstein).

Zu den aktuellen Ausgaben des Atherosclerosis Newsletters

Thema Ausgabe September/Oktober:
For many years, lipoprotein(a) (Lp(a)) has been known as an independent risk factor for atherosclerotic cardiovascular diseases (ASCVD). Its concentration in plasma is strongly determined by variations in the LPA gene, which encodes apolipoprotein(a) (apo(a)), i.e. the specific protein component of Lp(a). Results of Mendelian Randomization studies point to the causality of Lp(a) in the pathogenesis of ASCVD. Unfortunately, currently available drugs allow no or only moderate lowering of Lp(a) plasma levels and it is not well known whether these effects contribute to cardiovascular risk reduction exerted by some drugs. Moreover, the genetically determined size polymorphism of apo(a) makes it difficult to standardize Lp(a) for the measurement by traceable clinical routine methods. As a result, risk threshold varies considerably depending on the methods used. The September and October issues of Atherosclerosis contain several articles and editorials on Lp(a).

Link zum September/Oktober-Newsletter

Thema Ausgabe August/September:
Familial hypercholesterolemia is one of the most frequent monogenic diseases and the understanding of its etiology and pathogenesis played a pivotal role in the development of drugs that lower LDL-cholesterol and risk of atherosclerotic cardiovascular disease. Nevertheless, both FH and the LDL receptor continue to be in the interest of atherosclerosis research. The August and September issues of Atherosclerosis contain several articles describing diagnostic criteria and clinical consequences of FH, evaluating soluble versions of an LDL receptor related protein towards its relevance as a biomarker or exploiting the knock out of the LDL-receptor as a model for atherosclerosis research in mice.

Link zum August/September-Newsletter

Thema Ausgabe Juli:
Biomarkers are important tools of risk assessment, diagnosis of disease, stratification for different therapeutic options, and monitoring of safety and efficacy of treatment. This issue of Atherosclerosis contains several articles on studies aimed at validation of established biomarkers, as part of novel models or towards novel disease endpoints, or at validation of novel biomarker candidates.

Link zum July-Newsletter

Thema Ausgabe August/September:
Familial hypercholesterolemia is one of the most frequent monogenic diseases and the understanding of its etiology and pathogenesis played a pivotal role in the development of drugs that lower LDL-cholesterol and risk of atherosclerotic cardiovascular disease. Nevertheless, both FH and the LDL receptor continue to be in the interest of atherosclerosis research. The August and September issues of Atherosclerosis contain several articles describing diagnostic criteria and clinical consequences of FH, evaluating soluble versions of an LDL receptor related protein towards its relevance as a biomarker or exploiting the knock out of the LDL-receptor as a model for atherosclerosis research in mice.

Link zum August/September-Newsletter

Nach oben